To test whether the combination of DNA repair and mTOR inhibitors could be a relevant therapeutic strategy in tumors with genomic alterations in DNA repair and PI3K/AKT/mTOR pathway, we treat a PDX model established from a BRCA2 mutated breast cancer (HBCx-22 TamR) with the Parp inhibitor olaparib combined to the mTOR inhibitor everolimus. This evidence concerns the gene BRCA2 and breast cancer.